Molecular Weight: 464.436
Method of Analysis:In house
Application: Metastatic Castration Resistant Prostate Cancer (CRPC)
Mechanism: an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors; and consequently, inhibits nuclear translocation of androgen receptors and their interaction with DNA. A major metabolite, N-desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in a mouse prostate cancer xenograft model.
Storage conditions: Preserve in well-closed, light resistance containers. Store at controlled room temperature.
Packaging: The final product is packed in polyethylene nylon plastic bag and then packaged in a 3-layered aluminum foil.